EICHORPublic-registry trials using Dapagliflozin that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
Dapagliflozin appears in 1 registered trial Eichor's radar has found, sponsored by Youngene Therapeutics Inc., Ltd., the most recent registered as Phase 2, with a planned enrollment of 19. Registered timeline: 2021–2022. The registry holds 24,217 registered studies for Diabetes.
| Trial | Sponsor | Condition | Phase | Sites |
| A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes | Youngene Therapeutics Inc., Ltd. | Diabetes | PHASE2 | 1 |
| Status | Completed · planned start 2021-06 |
| Primary completion | 2022-02 |
| Enrollment target | 19 participants |
| Design | Randomized · Crossover · Phase 2 · 3 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 1 listed in United States |
All fields verbatim from the ClinicalTrials.gov record for NCT04956263.
| First FDA approval | FARXIGA — January 2014 (application NDA202293, currently held by ASTRAZENECA AB) |
| Approved applications | 31 — a multi-source (generic) drug |
| Forms & routes | Tablet, Tablet, Extended Release · Oral |
| Registry-wide use | 749 registered studies all-time · 114 currently recruiting |
Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.
The public registry holds 24,217 registered studies for Diabetes. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
← Eichor home · All tracked trials · Diabetes studies · Weekly briefs
